logo-loader
viewStarton Therapeutics

Full interview: ChemioCare begins dosing humans with its Olanzapine-based therapy

ChemioCare CEO Pedro Lichtinger tells Proactive the New York-based biotechnology company focused on transdermal delivery has begun dosing healthy human volunteers with its lead therapy CMIO-OLANZ, an Olanzapine transdermal patch, to treat Poly (ADP-ribose) polymerase (PARP) inhibitor-induced nausea and vomiting.

Lichtinger says cancer patients treated with PARP inhibitors are projected to capture 60% of first-line therapy in ovarian cancer. In ChemioCare's study, the company will measure blood levels of transdermal delivery and skin irritation, the gate-keeper to enter Phase 3 clinical programs.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Starton Therapeutics named herein, including the promotion by the Company of Starton Therapeutics in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Starton Therapeutics CEO talks through 2019 achievements and anticipated...

Starton Therapeutics CEO Pedro Lichtinger sat down with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco. Lichtinger talks about how the New York-based company recently changed its name from ChemioCare, how the company is well capitalized to continue through Q1 to next...

on 01/15/2020

2 min read